LBTSF
Price
$9.01
Change
-$0.16 (-1.74%)
Updated
Feb 10 closing price
Capitalization
2.01B
MEDXF
Price
$2.02
Change
+$0.04 (+2.02%)
Updated
May 1 closing price
Capitalization
31.92M
59 days until earnings call
Ad is loading...

LBTSF vs MEDXF

Header iconLBTSF vs MEDXF Comparison
Open Charts LBTSF vs MEDXFBanner chart's image
Almirall SA
Price$9.01
Change-$0.16 (-1.74%)
Volume$111
Capitalization2.01B
Medexus Pharmaceuticals
Price$2.02
Change+$0.04 (+2.02%)
Volume$14.25K
Capitalization31.92M
LBTSF vs MEDXF Comparison Chart
Loading...
MEDXF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LBTSF vs. MEDXF commentary
May 03, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LBTSF is a Hold and MEDXF is a Hold.

Ad is loading...
COMPARISON
Comparison
May 03, 2025
Stock price -- (LBTSF: $9.01 vs. MEDXF: $2.02)
Brand notoriety: LBTSF and MEDXF are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: LBTSF: 100% vs. MEDXF: 79%
Market capitalization -- LBTSF: $2.01B vs. MEDXF: $31.92M
LBTSF [@Pharmaceuticals: Other] is valued at $2.01B. MEDXF’s [@Pharmaceuticals: Other] market capitalization is $31.92M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LBTSF’s FA Score shows that 1 FA rating(s) are green whileMEDXF’s FA Score has 1 green FA rating(s).

  • LBTSF’s FA Score: 1 green, 4 red.
  • MEDXF’s FA Score: 1 green, 4 red.
According to our system of comparison, MEDXF is a better buy in the long-term than LBTSF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MEDXF’s TA Score shows that 3 TA indicator(s) are bullish.

  • MEDXF’s TA Score: 3 bullish, 2 bearish.

Price Growth

LBTSF (@Pharmaceuticals: Other) experienced а 0.00% price change this week, while MEDXF (@Pharmaceuticals: Other) price change was +4.66% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.04%. For the same industry, the average monthly price growth was +3.46%, and the average quarterly price growth was -7.03%.

Reported Earning Dates

MEDXF is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+2.04% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LBTSF($2.01B) has a higher market cap than MEDXF($31.9M). LBTSF has higher P/E ratio than MEDXF: LBTSF (49.75) vs MEDXF (26.67). LBTSF YTD gains are higher at: -1.777 vs. MEDXF (-16.356). LBTSF has higher annual earnings (EBITDA): 150M vs. MEDXF (14.6M). LBTSF has more cash in the bank: 447M vs. MEDXF (13.1M). MEDXF has less debt than LBTSF: MEDXF (70.1M) vs LBTSF (398M). LBTSF has higher revenues than MEDXF: LBTSF (893M) vs MEDXF (108M).
LBTSFMEDXFLBTSF / MEDXF
Capitalization2.01B31.9M6,310%
EBITDA150M14.6M1,027%
Gain YTD-1.777-16.35611%
P/E Ratio49.7526.67187%
Revenue893M108M827%
Total Cash447M13.1M3,412%
Total Debt398M70.1M568%
FUNDAMENTALS RATINGS
LBTSF vs MEDXF: Fundamental Ratings
LBTSF
MEDXF
OUTLOOK RATING
1..100
4318
VALUATION
overvalued / fair valued / undervalued
1..100
32
Undervalued
61
Fair valued
PROFIT vs RISK RATING
1..100
10093
SMR RATING
1..100
8963
PRICE GROWTH RATING
1..100
7143
P/E GROWTH RATING
1..100
604
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LBTSF's Valuation (32) in the null industry is in the same range as MEDXF (61). This means that LBTSF’s stock grew similarly to MEDXF’s over the last 12 months.

MEDXF's Profit vs Risk Rating (93) in the null industry is in the same range as LBTSF (100). This means that MEDXF’s stock grew similarly to LBTSF’s over the last 12 months.

MEDXF's SMR Rating (63) in the null industry is in the same range as LBTSF (89). This means that MEDXF’s stock grew similarly to LBTSF’s over the last 12 months.

MEDXF's Price Growth Rating (43) in the null industry is in the same range as LBTSF (71). This means that MEDXF’s stock grew similarly to LBTSF’s over the last 12 months.

MEDXF's P/E Growth Rating (4) in the null industry is somewhat better than the same rating for LBTSF (60). This means that MEDXF’s stock grew somewhat faster than LBTSF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MEDXF
RSI
ODDS (%)
Bullish Trend 23 days ago
68%
Stochastic
ODDS (%)
Bullish Trend 23 days ago
77%
Momentum
ODDS (%)
N/A
MACD
ODDS (%)
Bearish Trend 23 days ago
74%
TrendWeek
ODDS (%)
Bullish Trend 23 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 23 days ago
82%
Advances
ODDS (%)
N/A
Declines
ODDS (%)
Bearish Trend 30 days ago
82%
BollingerBands
ODDS (%)
Bullish Trend 23 days ago
70%
Aroon
ODDS (%)
N/A
View a ticker or compare two or three
Ad is loading...
MEDXF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
VPL76.391.30
+1.73%
Vanguard FTSE Pacific ETF
TEI5.450.01
+0.18%
Templeton Emerging Markets Income Fund
GSST50.320.01
+0.02%
Goldman Sachs Ultra Short Bond ETF
PHDG33.15-0.24
-0.72%
Invesco S&P 500® Downside Hedged ETF
HIBS16.53-1.47
-8.17%
Direxion Daily S&P 500® Hi Bt Br 3X ETF

LBTSF and

Correlation & Price change

A.I.dvisor indicates that over the last year, LBTSF has been loosely correlated with HLTRF. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if LBTSF jumps, then HLTRF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LBTSF
1D Price
Change %
LBTSF100%
N/A
HLTRF - LBTSF
39%
Loosely correlated
N/A
ETON - LBTSF
30%
Poorly correlated
+2.18%
INDV - LBTSF
18%
Poorly correlated
+3.72%
IPSEY - LBTSF
15%
Poorly correlated
+0.14%
MEDXF - LBTSF
10%
Poorly correlated
N/A
More

MEDXF and

Correlation & Price change

A.I.dvisor tells us that MEDXF and LBTSF have been poorly correlated (+10% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MEDXF and LBTSF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MEDXF
1D Price
Change %
MEDXF100%
N/A
LBTSF - MEDXF
10%
Poorly correlated
N/A
MRMD - MEDXF
9%
Poorly correlated
+3.33%
MKGAF - MEDXF
7%
Poorly correlated
-2.36%
MCUJF - MEDXF
4%
Poorly correlated
N/A
MEDIF - MEDXF
2%
Poorly correlated
+7.36%
More